Thomas Boerner

Dr. Thomas Boerner

orcid

Research Focus & Metrics

Academic Career Length

35Years (1992-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 February 2022 in HPB
Verified
Journal Article
Closed access
JJJoshua Jolissaint
Joshua Jolissaint
TWTiegong Wang
Tiegong Wang
KSKevin C. Soares
Kevin C. Soares
JCJoanne F. Chou
Joanne F. Chou
MGMithat Gönen
Mithat Gönen
JCJayasree Chakraborty
Jayasree Chakraborty

1 August 2021 in Gynecologic Oncology Reports
Verified
Journal Article
Open access
ACAndrew J. Chi
Andrew J. Chi
ALAlexandra J. Lopes
Alexandra J. Lopes
LRLisa Rong
Lisa Rong
MCMary E. Charlson
Mary E. Charlson
RARonald Alvarez
Ronald Alvarez
TBThomas Boerner
Thomas Boerner
• The AAS is a useful tool to predict future citation counts for oncology publications in gynecologic oncology. • A hybrid metric using impact factor and AAS may help to predict academic influence on a broader scale. • In addition to impact factor, AAS may be used by journals to enhance interest in subscriptions. • AAS may be another metric used to assess the quality of publications.

12 June 2024 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
YSYi Song
Yi Song
TBThomas Boerner
Thomas Boerner
EDEsther Drill
Esther Drill
PSPaul Shin
Paul Shin
SKSandeep Kumar
Sandeep Kumar
WJWilliam R. R Jarnagin
William R. R Jarnagin
Purpose: Intrahepatic cholangiocarcinoma (IHC) is a heterogeneous tumor. The hidden-genome classifier, a supervised machine learning–based algorithm, was used to quantify tumor heterogeneity and improve classification. Experimental Design: A retrospective review of 1,370 patients with IHC, extrahepatic cholangiocarcinoma (EHC), gallbladder cancer (GBC), hepatocellular carcinoma (HCC), or biphenotypic tumors was conducted. A hidden-genome model classified 527 IHC based on genetic similarity to EHC/GBC or HCC. Genetic, histologic, and clinical data were correlated. Results: In this study, 410 IHC (78%) had >50% genetic homology with EHC/GBC; 122 (23%) had >90% homology (“biliary class”), characterized by alterations of KRAS, SMAD4, and CDKN2A loss; 117 IHC (22%) had >50% genetic homology with HCC; and 30 (5.7%) had >90% homology (“HCC class”), characterized by TERT alterations. Patients with biliary- versus non-biliary-class IHC had median overall survival (OS) of 1 year (95% CI, 0.77, 1.5) versus 1.8 years (95% CI, 1.6, 2.0) for unresectable disease and 2.4 years (95% CI, 2.1, NR) versus 5.1 years (95% CI, 4.8, 6.9) for resectable disease. Large-duct IHC (n = 28) was more common in the biliary class (n = 27); the HCC class was composed mostly of small-duct IHC (64%, P = 0.02). The hidden genomic classifier predicted OS independent of FGFR2 and IDH1 alterations. By contrast, the histology subtype did not predict OS. Conclusions: IHC genetics form a spectrum with worse OS for tumors genetically aligned with EHC/GBC. The classifier proved superior to histologic subtypes for predicting OS independent of FGFR2 and IDH1 alterations. These results may explain the differential treatment responses seen in IHC and may direct therapy by helping stratify patients in future clinical trials.


12 November 2021 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
TBThomas Boerner
Thomas Boerner
PPPompiliu Piso
Pompiliu Piso
Due to limited systemic treatment options, peritoneal carcinomatosis of gastric origin is still associated with a dismal outcome and is claimed a terminal disease. In the past, surgery had not been considered as a potential treatment option. However, there is emerging evidence that in selected patients, locoregional treatment modalities including cytoreductive surgery of peritoneal carcinomatosis can improve survival in patients with gastric cancer. These operative procedures are complex and challenging, and a high surgical expertise of the treating physician is necessary to prevent major postoperative morbidity and mortality with a delay of further systemic therapy. This review summarizes our current knowledge and personal experience regarding the techniques of cytoreductive surgery for peritoneal metastasis of gastric origin.

1 April 2021 in Journal of Gastrointestinal Oncology
Verified
Journal Article
Open access
PDF file
TBThomas Boerner
Thomas Boerner
PPPompiliu Piso
Pompiliu Piso
Peritoneal carcinomatosis of gastric origin is an aggressive tumor entity. Historically it has been considered a terminal disease with no long-term survival, due to limited therapeutic options. However, as a better understanding of tumor biology has evolved in recent years, novel multimodal treatment strategies incorporating intraperitoneal (IP) chemotherapy—hyperthermic intraperitoneal chemotherapy (HIPEC), early postoperative intraperitoneal chemotherapy (EPIC), neoadjuvant intraperitoneal-systemic chemotherapy protocol (NIPS)—and cytoreductive surgery (CRS) have demonstrated promising oncologic outcomes and even long-term survival in selected patients. Most of the studies published to date are retrospective in nature. These studies involve heterogenous patient populations, a wide variety of chemotherapeutic drugs, and show wide variation in outcomes between institutions. Thus, it is difficult to evaluate the results. This review summarizes our current knowledge regarding IP chemotherapy and CRS for peritoneal metastases (PM) in gastric cancer (GC). We describe our institutional treatment regimens. We also provide a brief overview of new, targeted therapies that may show promise in the future.